



(51) International Patent Classification:

C07K 7/08 (2006.01) **A61K 38/09** (2006.01)
C07K 7/06 (2006.01) **A61K 38/10** (2006.01)
C07K 7/64 (2006.01) **A61P 35/00** (2006.01)
A61K 38/08 (2006.01)

(21) International Application Number:

PCT/SG2013/000428

(22) International Filing Date:

1 October 2013 (01.10.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201207302-9 1 October 2012 (01.10.2012) SG

(71) Applicant: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis, Singapore 138632 (SG).

(72) Inventors: **JOSEPH, Thomas Leonard**; BII, 30 Biopolis Street #07-01 Matrix, Singapore 138671 (SG). **VERMA, Chandra Shekhar**; BII, 30 Biopolis Street #07-01 Matrix, Singapore 138671 (SG). **LANE, David Phillip**; P53 Laboratory, 8A, Biomedical Grove, #06-04/05, Neuros/Immunos, Singapore 138648 (SG). **BROWN, Christopher John**; p53 Laboratory, 8A, Biomedical Grove, #06-04/05, Neuros/Immunos, Singapore 138648 (SG).

(74) Agent: **SPRUSON & FERGUSON (ASIA) PTE LTD**; P. O Box 1531, Robinson Road Post Office, Singapore 903031 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: PEPTIDES AND METHODS FOR TREATING CANCER



(57) Abstract: By using a phage display derived peptide as an initial template, compounds have been developed that are highly specific against Mdm2/Mdm4. These compounds exhibit greater potency in p53 activation and protein-protein interaction assays than a compound derived from the p53 wild-type sequence. Unlike nutlin, a small molecule inhibitor of Mdm2/Mdm4, the phage derived compounds can arrest cells resistant to p53 induced apoptosis over a wide concentration range without cellular toxicity, suggesting they are highly suitable for cyclotherapy.

